Results 111 to 120 of about 444,966 (303)

Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations.
Ashley Jones, Samuele Bonomi, Keith E. Stockerl‐Goldstein, Randall J. Bateman   +3 more
wiley   +1 more source

Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest

Respiratory Research, 2018
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, including gefitinib, are first-line drugs against advanced non-small cell lung cancer with activating EGFR mutations. However, the development of resistance to such drugs is a
Jian Zhou, Meijia Chang, Jing Li, Tao Fang, Jie Hu, Chunxue Bai   +5 more
doaj   +1 more source

Complex Systems Analysis of Arrested Neural Cell Differentiation during Development and Analogous Cell Cycling Models in Carcinogenesis [PDF]

, 2004
A new approach to the modular, complex systems analysis of nonlinear dynamics of arrested neural cell Differentiation--induced cell proliferation during organismic development and the analogous cell cycling network transformations involved in ...
Baianu, Professor I.C., Prisecaru, M.S. V   +1 more
core  

Unraveling the Molecular Mechanisms of Glioma Recurrence: A Study Integrating Single‐Cell and Spatial Transcriptomics

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Glioma recurrence severely impacts patient prognosis, with current treatments showing limited efficacy. Traditional methods struggle to analyze recurrence mechanisms due to challenges in assessing tumor heterogeneity, spatial dynamics, and gene networks.
Lei Qiu, Yinjiao Fei, Jiaxuan Ding, Kexin Shi, Jinyan Luo, Yuchen Zhu, Xingjian Sun, Gefei Jiang, Yuandong Cao, Weilin Xu, Shu Zhou   +10 more
wiley   +1 more source

Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML

Clinical Medicine Insights: Oncology, 2011
The treatment of chronic myelogenous leukemia (CML) was revolutionized by the development of imatinib mesylate, a small molecule inhibitor of several protein tyrosine kinases, including the ABL1 protein tyrosine kinase.
Marie P. Shieh, Masato Mitsuhashi, Michael Lilly   +2 more
doaj   +1 more source

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. [PDF]

, 2014
Activating mutations in FLT3 confer poor prognosis for individuals with acute myeloid leukemia (AML). Clinically active investigational FLT3 inhibitors can achieve complete remissions but their utility has been hampered by acquired resistance and ...
He, Bai-Liang, He, Bai-Liang, Lasater, Elisabeth A, Leung, Anskar Yh, Lin, Kimberly, Lopez, Michael S, Shah, Neil P, Shokat, Kevan M, Smith, Catherine C, Warkentin, Alexander A   +9 more
core  

A Smart Bio‐Battery Facilitates Diabetic Bone Defect Repair Via Inducing Macrophage Reprogramming and Synergistically Modulating Bone Remodeling Coupling

Advanced Functional Materials, EarlyView.
This research presents a novel implantable bio‐battery, GF‐OsG, tailored for diabetic bone repair. GF‐OsG generates microcurrents in high‐glucose conditions to enhance vascularization, shift macrophages to the M2 phenotype, and regulate immune responses.
Nanning Lv, Haifu Sun, Wenxiang Tang, Yonggang Li, Zhonglai Qian, Lihui Hong, Chong Chen, Hongye Li, Jiaxiang Bai, Yusen Qiao, Mingming Liu   +10 more
wiley   +1 more source

Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors

Frontiers in Pharmacology
The tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases (TFKs) are a subfamily of non-receptor protein tyrosine kinases (PTKs) that include five members: TEC, bruton’s tyrosine kinase (BTK), interleukin 2-inducible T-cell kinase ...
Yi Zhang, Huangxi Fu, Xingchen Kang, Zixuan Qiu, Hao Yan, Qiaojun He, Qiaojun He, Qiaojun He, Bo Yang, Bo Yang, Bo Yang, Zhifei Xu, Peihua Luo, Peihua Luo   +13 more
doaj   +1 more source

Gold Nanoclusters as Dual Agents for Engineering Tumor Vascular Leakiness and Performing Photothermal Therapy

Advanced Functional Materials, EarlyView.
Many cancer nanotherapeutics, while potent, suffer from the inability to escape from the tumor vasculature, especially in the absence of endothelial permeability. In this work, ultrasmall gold nanoclusters could engineer nanomaterials induced endothelial leakiness (NanoEL) and harness strong NIR induced photothermal characteristics to suppress tumor ...
Nengyi Ni, Kuoran Xing, Bihan Zhang, Baoteng Wang, Yinglu Chen, Jianping Xie, Xiao Sun, Jinping Wang, David Tai Leong   +8 more
wiley   +1 more source

A Heparin‐Functionalized Scaffold with HB‐EGF Immobilization for Tissue Engineering

Advanced Healthcare Materials, EarlyView.
In this study, a heparin‐functionalized scaffold is designed for bio‐mimicking growth factors reservoir function of extracellular matrix. Due to the presence of heparin‐binding domain, heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) is effectively and spatially captured by heparin‐functionalized scaffold.
Bowu Peng, Huajian Chen, Chengyu Lu, Tianjiao Zeng, Man Wang, Toru Yoshitomi, Naoki Kawazoe, Yingnan Yang, Guoping Chen   +8 more
wiley   +1 more source